Check out our comprehensive educational activities here

How does maintenance therapy fit into the framework of AML treatment?

In AML, the role of maintenance therapy has been unclear. In this activity, Dr. Stein reviews data from the QUAZAR study and which patients with AML may benefit from this treatment.

Published on August 2, 2021 in Treatment

A Case Study in Secondary AML: Best Practice for Treatment Selection

In this activity, Dr. Lancet discusses choice of therapy for a patient who presents with secondary AML.

This activity is supported by educational grants from Actinium Pharmaceuticals, Bristol-Myers Squibb, and Jazz Pharmaceuticals.

Published on January 20, 2021 in Treatment

Is it possible to deliver liposomal daunorubicin and cytarabine on an outpatient basis?

In this activity, Dr. Eunice Wang explains the adverse events associated with liposomal cytarabine and daunorubicin and how to manage them on an outpatient basis.

Published on December 7, 2020 in Treatment

What are the key factors you must take into consideration in determining upfront treatment for patients with high-risk, secondary AML?

Dr. Wang describes how she determines upfront therapy for a patient with newly diagnosed secondary AML.

Published on November 30, 2020 in Treatment

Expert Opinions on Common Clinical Challenges in AML

In this newsletter, three experts address common clinical challenges practitioners face in AML such as maintenance regimens for FLT3-mutated AML or MRD-eradicating strategies.

Published on October 14, 2020 in Treatment

Key Updates from ASCO 2020 and EHA 2020: Experts Discuss Data and Implications Important to Clinical Practice

In this newsletter, Dr. Daver and Dr. Perl discuss their choices of the most important data to come out of the ASCO 2020 and EHA 2020 meetings in AML and their clinical implications.

Published on October 7, 2020 in Treatment

New Advances in AML Discussion

In this activity, three experts will discuss advances in therapeutic strategies for individual patients with newly diagnosed and relapsed/refractory AML.

For an educational activity on New Advances in AML please click here

Published on July 10, 2020 in Treatment

High Rate of IDH1 Mutation Clearance and MRD Negativity in Patients with IDH1 Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Join Dr. Stein as he explains administering ivosidenib and azacitidine together in a safe manner, and how this could impact practice for patients with newly diagnosed AML.

Published on May 27, 2020 in Treatment

How does quizartinib fit into the treatment paradigm of AML and what are the key aspects that clinicians need to know about this agent?

In this activity, Dr. Perl explains one of the most potent and selective FLT3 inhibitors developed and where it will fit in the treatment landscape if approved.

Published on May 6, 2020 in Treatment

How are the results of the phase 3 ADMIRAL trial changing the treatment paradigm for salvage therapy of AML?

It is important to screen for FLT3 mutations in patients who have relapsed/refractory AML. Join Dr. Perl as he covers the results of the phase 3 ADMIRAL trial and how this will impact practice.

Published on May 6, 2020 in Treatment